Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical TrialPlain-Language Summary

Rationale & Objective: In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)–based regimens. Our objective was to compare the calculated CV risk betw...

Cijeli opis

Bibliografski detalji

Glavni autori:	Obbo W. Bredewold, MD, Joe Chan, My Svensson, Annette Bruchfeld, Johan W. de Fijter, Hans Furuland, Josep M. Grinyo, Anders Hartmann, Hallvard Holdaas, Olof Hellberg, Alan Jardine, Lars Mjörnstedt, Karin Skov, Knut T. Smerud, Inga Soveri, Søren S. Sørensen, Anton-Jan van Zonneveld, Bengt Fellström
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2023-01-01
Serija:	Kidney Medicine
Teme:	Kidney transplantation randomized clinical trial belatacept calcineurin inhibitors tacrolimus cardiovascular disease
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2590059522002072
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!